Home > Healthcare > Pharmaceuticals > Finished Drug Form > liver cancer drugs market
Get a free sample of Liver Cancer Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Liver Cancer Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The liver cancer drugs industry is highly competitive, with prominent players are driving market growth through strong sales of oncology drugs for liver cancer. The growing strategic initiatives, collaborations, advanced treatments, and a focus on R&D underscored the competitive dynamics in the market, thereby driving advancements and market growth.
Some of the prominent players operating in the liver cancer drugs industry include:
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc, Novartis AG, Sanofi SA, and Thermo Fisher Scientific Inc.
North America liver cancer drugs market size exceeded USD 1.1 billion in 2023, attributed to the early adoption of advanced diagnostic tests and therapies for liver cancer.
The hepatocellular carcinoma segment in the liver cancer drugs market generated USD 1.9 billion in 2023 and is predicted to reach USD 5 billion by 2032, due to its prevalence among individuals with chronic liver diseases such as cirrhosis.
The market size of liver cancer drugs was reached USD 2.9 billion in 2023 and is estimated to grow at 11.8% CAGR from 2024 to 2032, owing to the rising incidence of liver cancer.